Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNASDAQ:ASNDNASDAQ:ATHANYSE:JNJNYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$189.50-0.7%$187.37$163.63▼$218.66$334.34B0.486.25 million shs3.71 million shsASNDAscendis Pharma A/S$174.07+0.6%$167.68$111.09▼$183.00$10.65B0.38500,084 shs157,816 shsATHAAthira Pharma$0.33+9.9%$0.30$0.22▼$3.67$13.27M2.991.58 million shs320,322 shsJNJJohnson & Johnson$155.90+0.2%$153.68$140.68▼$169.99$375.37B0.418.05 million shs3.48 million shsJNJJohnson & Johnson$155.90+0.2%$153.68$140.68▼$169.99$375.37B0.418.05 million shs3.48 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+4.19%+1.17%+1.57%+15.66%ASNDAscendis Pharma A/S0.00%+1.07%+0.22%+22.01%+29.73%ATHAAthira Pharma0.00%+12.20%+0.30%+32.40%-87.12%JNJJohnson & Johnson0.00%+2.27%+1.64%+1.88%+7.06%JNJJohnson & Johnson0.00%+2.27%+1.64%+1.88%+7.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.9067 of 5 stars3.45.03.33.92.81.71.3ASNDAscendis Pharma A/S3.6664 of 5 stars4.53.00.00.02.81.70.6ATHAAthira Pharma2.7455 of 5 stars3.03.00.00.00.73.31.3JNJJohnson & Johnson4.8503 of 5 stars2.35.04.23.93.11.71.9JNJJohnson & Johnson4.8503 of 5 stars2.35.04.23.93.11.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.81Moderate Buy$211.2911.50% UpsideASNDAscendis Pharma A/S 3.00Buy$220.6726.77% UpsideATHAAthira Pharma 2.00Hold$11.253,298.79% UpsideJNJJohnson & Johnson 2.55Moderate Buy$170.889.61% UpsideJNJJohnson & Johnson 2.55Moderate Buy$170.889.61% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, JNJ, ATHA, ASND, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/11/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$205.006/9/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold$204.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.006/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/14/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$210.00 ➝ $205.005/13/2025JNJJohnson & JohnsonLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025JNJJohnson & JohnsonLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$57.37B5.83$14.94 per share12.68$1.90 per share99.74ASNDAscendis Pharma A/S$368.70M28.86N/AN/A($1.88) per share-92.59ATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/AJNJJohnson & Johnson$88.82B4.22$13.11 per share11.89$29.69 per share5.25JNJJohnson & Johnson$88.82B4.22$13.11 per share11.89$29.69 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3580.6413.561.267.31%412.03%13.11%7/31/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A725.29N/A-93.22%N/A-33.29%9/2/2025 (Estimated)ATHAAthira Pharma-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%7/30/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9917.3414.082.3624.42%33.46%13.30%7/16/2025 (Estimated)JNJJohnson & Johnson$14.07B$8.9917.3414.082.3624.42%33.46%13.30%7/16/2025 (Estimated)Latest ABBV, JNJ, ATHA, ASND, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025ABBVAbbVie$3.24N/AN/AN/A$14.93 billionN/A7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/A5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.46%N/A279.15%53 YearsASNDAscendis Pharma A/SN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.34%N/A57.84%64 YearsJNJJohnson & Johnson$5.203.34%N/A57.84%64 YearsLatest ABBV, JNJ, ATHA, ASND, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/20254/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/20254/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.760.64ASNDAscendis Pharma A/SN/A1.040.71ATHAAthira PharmaN/A7.267.26JNJJohnson & Johnson0.491.261.03JNJJohnson & Johnson0.491.261.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ASNDAscendis Pharma A/SN/AATHAAthira Pharma57.12%JNJJohnson & Johnson69.55%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%ASNDAscendis Pharma A/S40.00%ATHAAthira Pharma22.10%JNJJohnson & Johnson0.16%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableATHAAthira Pharma4039.04 million30.41 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableABBV, JNJ, ATHA, ASND, and JNJ HeadlinesRecent News About These CompaniesJohnson & Johnson Canadian Depository Receipt (CAD Hedged) JNJ1 hour ago | morningstar.comMTandem Investment Advisors Inc. Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)July 5 at 5:29 AM | marketbeat.comMeritage Portfolio Management Sells 1,844 Shares of Johnson & Johnson (NYSE:JNJ)July 5 at 5:24 AM | marketbeat.comZWJ Investment Counsel Inc. Buys 2,851 Shares of Johnson & Johnson (NYSE:JNJ)July 5 at 5:24 AM | marketbeat.comResonant Capital Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)July 5 at 5:23 AM | marketbeat.comRobert Wood Johnson Foundation Trims Stock Position in Johnson & Johnson (NYSE:JNJ)July 5 at 5:23 AM | marketbeat.comTeacher Retirement System of Texas Lowers Position in Johnson & Johnson (NYSE:JNJ)July 5 at 5:21 AM | marketbeat.comFirst Horizon Advisors Inc. Raises Stock Position in Johnson & Johnson (NYSE:JNJ)July 5 at 5:09 AM | marketbeat.comRevisor Wealth Management LLC Has $892,000 Stake in Johnson & Johnson (NYSE:JNJ)July 5 at 5:09 AM | marketbeat.comHudson Edge Investment Partners Inc. Has $6.66 Million Stock Position in Johnson & Johnson (NYSE:JNJ)July 5 at 5:09 AM | marketbeat.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarJuly 4 at 9:56 AM | zacks.com2 Bulletproof Dividend Stocks to Buy in JulyJuly 4 at 9:40 AM | 247wallst.comGoldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy TailwindsJuly 4 at 6:48 AM | msn.comPinnacle Financial Partners Inc Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comMiller Howard Investments Inc. NY Acquires 99,040 Shares of Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comKanawha Capital Management LLC Has $24.87 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comMoody Lynn & Lieberson LLC Has $22.09 Million Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:05 AM | marketbeat.comFirst Bank & Trust Buys 3,952 Shares of Johnson & Johnson (NYSE:JNJ)July 4 at 5:04 AM | marketbeat.comHarbour Trust & Investment Management Co Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)July 4 at 5:04 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Keybank National Association OHJuly 4 at 4:54 AM | marketbeat.comYukon Wealth Management Inc. Invests $741,000 in Johnson & Johnson (NYSE:JNJ)July 4 at 4:54 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyRegional Bank Buybacks: 5 Institutions Making Big MovesBy Leo Miller | June 24, 2025View Regional Bank Buybacks: 5 Institutions Making Big MovesABBV, JNJ, ATHA, ASND, and JNJ Company DescriptionsAbbVie NYSE:ABBV$189.50 -1.25 (-0.66%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$188.90 -0.60 (-0.32%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Ascendis Pharma A/S NASDAQ:ASND$174.07 +0.97 (+0.56%) Closing price 07/3/2025 02:42 PM EasternExtended Trading$174.07 0.00 (0.00%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Athira Pharma NASDAQ:ATHA$0.33 +0.03 (+9.93%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$0.33 0.00 (-0.30%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Johnson & Johnson NYSE:JNJ$155.90 +0.34 (+0.22%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$155.75 -0.15 (-0.10%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Johnson & Johnson NYSE:JNJ$155.90 +0.34 (+0.22%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$155.75 -0.15 (-0.10%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
